4/A: Stepan VP Amends Stock Holdings, Corrects SAR Amount

Stepan Co.'s VP & GM of Surfactants, Sean T. Moriarty, filed an amended Form 4 to correct previously reported Stock Appreciation Right amounts and disclose recent equity transactions.

Summary

• Sean T. Moriarty, VP & GM of Surfactants at Stepan Co. (SCL), filed an amended Form 4 to correct an incorrect Stock Appreciation Right (SAR) amount reported in the original filing on March 4, 2026.
• On February 27, 2026, Moriarty acquired 56.765 shares of Common Stock at a price of $52.51 per share.
• Following this transaction, Moriarty directly beneficially owns 14,205.2335 shares of Common Stock and indirectly owns 4,478.351 shares through an ESOP II Trust.
• On March 2, 2026, Moriarty was granted 6,440 Stock Appreciation Rights (SARs) with an exercise price of $17.47, which vest ratably over three years beginning March 2, 2027, and expire on March 3, 2036.
• Also on March 2, 2026, Moriarty was granted 2,247 Performance Shares, which represent a contingent right to receive one share of Stepan Company common stock upon achieving certain performance goals for the period ending December 31, 2028.
• Additionally, on March 2, 2026, Moriarty was granted 4,495 Restricted Stock Units (RSUs), which vest ratably over three years beginning March 2, 2027, and expire on March 2, 2029.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. It's a routine insider transaction and correction, with the positive aspect being the executive's acquisition of common stock and receipt of performance-linked equity awards.

Positives

• The acquisition of 56.765 shares of common stock by a key executive demonstrates a direct investment in the company's equity, aligning management's interests with shareholders.
• The grant of Stock Appreciation Rights, Performance Shares, and Restricted Stock Units represents a significant portion of executive compensation tied to future company performance and stock price appreciation, incentivizing long-term value creation.

Future Outlook

The vesting schedules for the Stock Appreciation Rights and Restricted Stock Units, extending to 2029 and 2036 respectively, indicate a long-term incentive structure for the executive. The Performance Shares are contingent on achieving specific company performance goals by December 31, 2028, suggesting a focus on future operational and financial targets.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the acquisition of company stock and the grant of equity-based compensation like SARs, RSUs, and Performance Shares, are standard practices in the chemical manufacturing industry. These mechanisms are widely used to align executive incentives with shareholder value creation and retain key talent. The correction of a previously filed amount is also a routine compliance adjustment for SEC filings.

Comparison to Industry Standards

• The structure of executive compensation, including grants of Stock Appreciation Rights, Performance Shares, and Restricted Stock Units, is consistent with common practices observed in publicly traded companies within the specialty chemicals sector, such as those seen at competitors like Albemarle Corporation or Ecolab Inc., which also utilize long-term equity incentives to motivate management.
• The direct acquisition of common stock by an executive, while modest in this instance, is a positive signal often seen across industries, reinforcing confidence in the company's future prospects, similar to insider buys reported by executives at companies like Dow Inc. or DuPont de Nemours, Inc.

Stakeholder Impact

• Shareholders gain increased transparency regarding executive stock ownership and compensation, which can foster confidence in management's alignment with shareholder interests.
• Employees, particularly those in management, may view the equity grants as a positive signal regarding the company's commitment to performance-based incentives.

Next Steps

• Vesting of Stock Appreciation Rights will commence ratably over three years starting March 2, 2027.
• Vesting of Restricted Stock Units will commence ratably over three years starting March 2, 2027.
• Performance Shares will vest upon certification of Stepan Company achieving certain performance goals for the period ending December 31, 2028.

Key Dates

Recommendation

This Form 4/A filing details routine insider equity transactions and a correction to a previous filing. It does not contain new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are standard executive compensation and personal investment activities.

Keywords

Stepan Co, SCL, Form 4/A, Insider Transaction, Stock Appreciation Rights, Restricted Stock Units, Performance Shares, Executive Compensation, Equity Grant, Common Stock